中国医药：药品价格政策有望优化，医疗AI加速商业化落地

Investment Rating - The report assigns a "Buy" rating to several companies in the pharmaceutical sector, indicating a potential upside of over 15% in their stock prices over the next 12 months [33]. Core Insights - The pharmaceutical industry in China is expected to benefit from optimized drug pricing policies, improved macroeconomic conditions, and anticipated interest rate cuts abroad, leading to a valuation recovery in 2025 [1][4]. - The introduction of the Class B medical insurance catalog is expected to enhance the payment environment for innovative drugs, while the accelerated recovery of medical device tenders will boost the profitability of domestic medical device companies [1][4]. - The report highlights the accelerating commercialization of medical AI, which is anticipated to bring significant cost reductions and optimization of medical resources, with a focus on companies that possess technological barriers and clear business models [4]. Summary by Sections Industry Overview - The report discusses the potential for drug pricing policy optimization, which is expected to support the recovery of pharmaceutical companies' profits. It mentions a draft document encouraging commercial insurance companies to establish investment funds for innovative drugs, which could lead to tax incentives for qualifying companies [4]. - The report emphasizes the importance of a multi-tiered medical security system and the inclusion of high-level innovative drugs in the Class B catalog, which will support the integration of these drugs into the medical insurance system at appropriate prices [4]. Company Recommendations - The report recommends buying shares of the following companies: - Innovent Biologics (1801 HK) - BeiGene (ONC US) - Sangamo Therapeutics (1530 HK) - United Imaging Healthcare (688271 CH) - Junshi Biosciences (2367 HK) - WuXi AppTec (603259 CH) - Kelun-Biotech (6990 HK) [2][4]. Market Performance - The MSCI China Healthcare Index has increased by 11.5% since the beginning of 2025, underperforming the MSCI China Index by 1.2% [1]. - The report notes that the medical AI sector is expected to see significant advancements, particularly in areas such as medical imaging, drug development, and intelligent diagnosis, which will enhance operational efficiency and resource allocation in healthcare [4].